Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to tame rheumatoid arthritis inflammation

NCT ID NCT07684157

Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called JAB-8263 in adults with active rheumatoid arthritis. The goal is to see if it is safe and can reduce joint inflammation and pain. Participants take the drug or a placebo every other day for 28 days. The trial is small and early-stage, so its main focus is safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JAB-8263 (oral drug)
What this could lead to
If successful, JAB-8263 could offer a new oral treatment option for people with active rheumatoid arthritis, potentially reducing joint pain and swelling.
What could go wrong
This is an early Phase IIa study with only 32 participants, so results may not apply to everyone. The drug may cause side effects or prove no better than placebo.
Why investors are watching

Jacobio Pharmaceuticals is running a small Phase IIa trial of JAB-8263 in 32 people with active rheumatoid arthritis. For a small company, this early safety and effectiveness readout matters because it is the first test of whether the drug works in humans with this condition. A clear result, positive or negative, will shape the company's next steps and its value to investors.

If it works: If JAB-8263 shows good safety and signs of controlling disease activity, Jacobio could advance the drug to a larger trial. That progress would validate its pipeline and attract more attention from partners or investors.

If it fails: The trial is small and early, so a weak or unclear result would likely end the program. Many Phase IIa trials fail to show enough benefit, and a failure here would leave Jacobio with fewer development options.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years old and \<75 years old at the time of signing the informed consent form, regardless of gender; 2. Active rheumatoid arthritis, ESR or C-reactive protein\> upper limit of normal 3. Meets the 2010 American College of Rheumatology ACR/EULAR RA classification standards 4. Participants have recovered from adverse reactions to previous antirheumatic treatment. Exclusion Criteria: 1. Use of topical glucocorticoids within 2 weeks before the first dose of investigational product or have received epidural, intraarticular, intramuscular, oral or intravenous glucocorticoids within 4 weeks, and do not use adrenocorticotropin; 2. Use of NSAIDs within 1 week before first dose of investigational product 3. Known or suspected allergies to the investigational product or any of its components; 4. Current active shingles virus infection, including shingles or herpes simplex types 1 and 2 (confirmed by physical examination and medical history); participants had a history of severe herpes infection, including any disseminated disease, shingles in multiple skin areas, herpes encephalitis, ocular herpes, or recurrent shingles (2 episodes greater than or equal to 2 episodes within 2 years); 5. Have evidence of active tuberculosis (TB) or have previously had evidence of active TB and have not received appropriate documented treatment;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis (RA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Beijing Hospital

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.